ArticleJournal of diabetes investigation2025
Dysregulation of lncRNA OIP5-AS1 participants in the progression of diabetic retinopathy and affects the proliferation in retinal vascular endothelial cell.
Article in Journal of diabetes investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis study was to ascertain the clinical performance of OIP5-AS1 in diabetic retinopathy (DR) and its molecular mechanism in the disease progression. MATERIALS AND
methodsSubjects included 85 healthy controls, 79 patients with type 2 diabetes mellitus (T2DM), and 114 T2DM-DR patients. qRT-PCR was conducted to measure the relative abundances of OIP5-AS1 and miR-181a-5p in the research subjects. Receiver operating characteristic (ROC) and logistic regression analyses were employed for the diagnostic capability and risk factor prediction. Cell activities were assessed using CCK-8 and transwell assays. Luciferase reporter assay was used for the correlation confirmation of OIP5-AS1 and miR-181a-5p. Bioinformatic analysis was applied to predict the potential targets of miR-181a-5p.
resultsA significant decrease of OIP5-AS1 was detected in serum from patients with T2MD and T2DM-DR (P < 0.001), exhibiting a high diagnostic value for detecting T2DM (AUC = 0.973) and T2DM-DR patients (AUC = 0.913). OIP5-AS1 was an independent protective indicator for the onset of T2DM-proliferative DR (T2DM-PDR; P = 0.021, OR = 0.306, 95%CI = 0.112-0.837). OIP5-AS1 was markedly reduced in human retinal vascular endothelial cells (HRVECs) with high glucose (HG) (P < 0.001). Overexpression of OIP5-AS1 could significantly suppress the cell growth of HRVECs (P < 0.001). OIP5-AS1 was negatively correlated with miR-181a-5p (r = -0.5327, P < 0.001). Additionally, the impacts caused by OIP5-AS1 on cell events were canceled by transfection of miR-181a-5p mimic (P < 0.001). The possible targets of miR-181a-5p were mined, suggesting mainly enriched in cellular senescence and the MAPK signaling pathway.
conclusionsOIP5-AS1 was downregulated in T2DM-DR patients and regulated cellular functions via targeting miR-181a-5p. It might offer a new therapeutic target for the disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.